Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 269

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 19
Chunk 269
---
-Ilan University, which provides to the Company with an exclusive, perpe...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  On March 19, 2024, the Company entered into a License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, which provides to the Company with an exclusive, ...  

  On March 31, 2024, the Company entered into a License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, which provides to the Company with an exclusive, ...  

  In respect to the Company’s lease commitment,  

F-34

CLEARMIND
MEDICINE INC.

Notes to
the Consolidated Financial Statements

(Expressed
in United States Dollars)

  15.      Segmented    

As
of October 31, 2024, the Company has one operating segment, research and development of psychedelic medicine, which takes place primarily
in Israel.

  16.      Income  

Tax
rates applicable to the Company:

The
combined Canadian federal and provincial statutory income tax rate is 27 23

The
tax effect (computed by applying the Canadian federal and provincial statutory rate) of the significant differences, which comprise deferred
income tax assets and liabilities, are as follows:

 ────────────────────────────────────────────────────────────────────────────────────────────────────────
  Canadian statutory income tax rate                              27               27               27  
  Income tax recovery at statutory rate                  ( 1,316,712      ( 2,322,936      ( 1,861,476  
  Tax effect of:                                                                                        
  Items not deductible for tax purposes                     ( 20,556          223,809          335,494  
  Over provided in prior years                             ( 384,109         ( 19,674                -  
  Tax rate difference for foreign jurisdiction               ( 5,365           10,715           56,175  
  Change in unrecognized deferred income tax assets        2,104,708        2,125,459        1,499,666  
  Income tax provision                                       377,966           17,372           29,859  

F-35

CLEARMIND
MEDICINE INC.

Notes to
the Consolidated Financial Statements

(Expressed
in United States Dollars)

  16.      Income